Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
PYC Therapeutics Limited ( (AU:PYC) ) has shared an announcement.
PYC Therapeutics Limited has reported the cessation of several tranches of employee and incentive options listed on the ASX, with exercise prices primarily at $1.70 and one at $0.90. These options, expiring between 2026 and 2031, have either lapsed because vesting conditions were not met or expired unexercised.
The move reduces the company’s pool of outstanding options and potential future share dilution for existing shareholders. The lapses suggest that certain performance or service conditions tied to these options were not achieved, which may reflect internal performance hurdles and could influence future structuring of equity-based compensation and capital management plans.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.84 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a biotechnology company focused on developing therapeutics, likely in the RNA or genetic medicine space, and is listed on the ASX. The company operates in a capital-intensive sector where equity incentives and options are commonly used to attract and retain talent and to align management and employees with shareholder interests.
Average Trading Volume: 1,387,433
Technical Sentiment Signal: Hold
Current Market Cap: A$1.21B
See more insights into PYC stock on TipRanks’ Stock Analysis page.